Compare Stocks → “Crash Insurance” For Your Retirement (From Unstoppable Prosperity) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ICVXNASDAQ:KODNASDAQ:MGTXNASDAQ:OPT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeICVXIcosavax$15.31$15.32$4.75▼$16.10$766.88M1.281.22 million shsN/AKODKodiak Sciences$3.98+1.0%$4.87$1.37▼$9.80$209.03M2.25784,344 shs425,330 shsMGTXMeiraGTx$5.38+6.1%$5.70$3.49▼$8.35$345.99M1.31151,050 shs205,193 shsOPTOpthea$3.34-3.2%$3.60$1.60▼$4.40$194.76M1.2422,543 shs26,998 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceICVXIcosavax0.00%0.00%0.00%+0.39%+119.66%KODKodiak Sciences+1.02%+23.99%-3.40%-15.50%-18.28%MGTXMeiraGTx+6.22%+10.25%-2.18%-16.72%-8.50%OPTOpthea-6.06%-2.77%-16.63%+13.82%-12.92%Incredible Opportunity to Retire FAST! (Ad)A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guideMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationICVXIcosavaxN/AN/AN/AN/AN/AN/AN/AN/AKODKodiak Sciences2.8998 of 5 stars2.90.00.04.61.23.31.3MGTXMeiraGTx3.818 of 5 stars3.53.00.04.80.01.70.6OPTOpthea2.1228 of 5 stars3.53.00.00.02.40.80.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceICVXIcosavax2.33Hold$26.5073.09% UpsideKODKodiak Sciences1.71Reduce$5.5038.19% UpsideMGTXMeiraGTx3.00Buy$25.67377.08% UpsideOPTOpthea3.00Buy$14.00319.79% UpsideCurrent Analyst RatingsLatest OPT, MGTX, ICVX, and KOD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2024KODKodiak SciencesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$3.00 ➝ $5.004/1/2024KODKodiak SciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetUnderweight ➝ Underweight$2.00 ➝ $3.003/15/2024MGTXMeiraGTxRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00(Data available from 5/8/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookICVXIcosavax$580K1,322.20N/AN/A$5.47 per share2.80KODKodiak SciencesN/AN/AN/AN/A$5.07 per shareN/AMGTXMeiraGTx$14.02M24.68N/AN/A$2.17 per share2.48OPTOpthea$110K1,770.58N/AN/A($0.10) per share-33.35Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateICVXIcosavax-$91.76M-$2.22N/AN/AN/AN/A-43.06%-39.53%N/AKODKodiak Sciences-$260.49M-$4.96N/AN/AN/AN/A-80.20%-46.17%5/20/2024 (Estimated)MGTXMeiraGTx-$84.03M-$1.47N/A5.98N/A-599.47%-114.33%-42.56%5/9/2024 (Estimated)OPTOpthea-$142.52MN/A0.00N/AN/AN/AN/AN/AN/ALatest OPT, MGTX, ICVX, and KOD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023KODKodiak Sciences-$0.86-$1.13-$0.27-$1.13N/AN/A3/14/2024Q4 2023MGTXMeiraGTx-$0.46-$0.47-$0.01-$1.36$10.13 million$2.04 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthICVXIcosavaxN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/AOPTOptheaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioICVXIcosavaxN/A18.0618.06KODKodiak SciencesN/A6.936.93MGTXMeiraGTx0.622.382.38OPTOptheaN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipICVXIcosavax92.59%KODKodiak Sciences89.06%MGTXMeiraGTx67.48%OPTOpthea55.95%Insider OwnershipCompanyInsider OwnershipICVXIcosavax30.59%KODKodiak Sciences45.30%MGTXMeiraGTx9.70%OPTOpthea3.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableICVXIcosavax6050.09 million34.77 millionOptionableKODKodiak Sciences11652.52 million28.73 millionOptionableMGTXMeiraGTx41964.31 million58.07 millionOptionableOPTOpthea2458.40 million56.53 millionNot OptionableOPT, MGTX, ICVX, and KOD HeadlinesSourceHeadlineContrasting Fusion Pharmaceuticals (NASDAQ:FUSN) & Opthea (NASDAQ:OPT)americanbankingnews.com - May 8 at 1:34 AMOpthea Announces Upcoming Presentations at the Retina World Congress 2024finance.yahoo.com - May 1 at 7:34 AMOpthea Announces Upcoming Presentations at the Retina World Congress 2024globenewswire.com - May 1 at 7:30 AMOpthea (NASDAQ:OPT) versus Cognition Therapeutics (NASDAQ:CGTX) Financial Analysisamericanbankingnews.com - May 1 at 1:48 AMDr Boreham’s Crucible: In rare Phase 3 air, can Opthea now see its way clear to a $15bn market?msn.com - April 28 at 10:17 AMOpthea to Present at the OIS Retina Innovation Summit at ARVOglobenewswire.com - April 25 at 9:00 AMLeerink Partnrs Research Analysts Decrease Earnings Estimates for Opthea Limited (NASDAQ:OPT)marketbeat.com - April 12 at 6:40 AMOpthea Appoints John Han, PharmD, as VP Medical Affairsglobenewswire.com - April 8 at 6:42 PMOpthea Limited American Depositary Shares (OPT)nasdaq.com - April 5 at 1:37 PMOpthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conferenceglobenewswire.com - April 4 at 6:34 PMWhy A2 Milk, Lindsay Australia, Meridian Energy, and Opthea shares are falling todaymsn.com - April 3 at 11:14 PMOpthea Appoints Sujal Shah to the Board of Directorsglobenewswire.com - April 3 at 5:39 PM7 Growth Stocks to Buy to Outperform the Nasdaq Indexinvestorplace.com - April 3 at 9:53 AMOpthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024globenewswire.com - March 19 at 6:00 AMEnd in sight as Opthea looks to be key player in US$10 billion wet AMD marketmsn.com - March 6 at 6:43 PMOpthea to Participate in the Leerink Partners Global Biopharma Conferenceglobenewswire.com - March 5 at 5:08 PMOpthea Reports Half-Year Financial Results and Business Updatesglobenewswire.com - February 28 at 5:55 PMOpthea Limited (OPT)au.finance.yahoo.com - February 22 at 3:16 PMOpthea Limited: Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisorfinanznachrichten.de - February 20 at 5:31 AMOpthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisorglobenewswire.com - February 19 at 6:25 PMOpthea Limited: Opthea Completes Enrollment in First Pivotal Trial with Soziniberceptfinanznachrichten.de - February 14 at 10:23 AMOpthea Completes Enrollment in First Pivotal Trial with Soziniberceptfinance.yahoo.com - February 14 at 10:23 AMOpthea Completes Enrollment in First Pivotal Trial with Soziniberceptglobenewswire.com - February 14 at 7:00 AMWhy Is Retinal Diseases-Focused Opthea Stock Trading Higher Today?msn.com - December 27 at 12:28 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHow to Use Put Debit Spreads to Profit From Falling Stocks April 26, 2024 9:30 AMView How to Use Put Debit Spreads to Profit From Falling Stocks Here are the Pros and Cons of Using Options Call Debit SpreadsApril 11, 2024 11:03 PMView Here are the Pros and Cons of Using Options Call Debit SpreadsASML Fires Warning Shot For Tech InvestorsApril 17, 2024 9:05 AMView ASML Fires Warning Shot For Tech InvestorsWestern Digital Slips Despite EPS Beat and Raise - Buy Time? April 29, 2024 7:45 AMView Western Digital Slips Despite EPS Beat and Raise - Buy Time? Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism RemainsApril 17, 2024 7:40 AMView Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism RemainsAll Headlines Company DescriptionsIcosavaxNASDAQ:ICVXIcosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.Kodiak SciencesNASDAQ:KODKodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.MeiraGTxNASDAQ:MGTXMeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.OptheaNASDAQ:OPTOpthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.